ClinicalTrials.Veeva

Menu

Technological Development and Clinical Parallel Testing of PGT-G

Sun Yat-sen University logo

Sun Yat-sen University

Status

Enrolling

Conditions

Genetic Disease

Study type

Observational

Funder types

Other

Identifiers

NCT05609708
SYSKY-2022-245-02

Details and patient eligibility

About

Preimplantation genetic testing (PGT) has three different testings according to the type of genetic disease, which was classified as PGT-M, PGT-SR and PGT-A. If the couple is tested for two different genetic diseases at the same time, it is necessary to customize the probe and adopt different detection methods, which increases the cost and cycle of testing. Advanced expert pre-experimental analysis is required for PGT-M in couples with monogenic disease. If the family members are unavailable, only the polar bodies, sperms or affected embryos can be used to analysis, which not only increases the risk of failure, but also increases the difficulty of detection. At present, BGI has developed a new single-tube complete Long fragment whole genome sequencing (stLFR-WGS) technology, which uses the same molecular tag on the short read sequencing fragments from the same long DNA molecule to achieve accurate short read sequencing to obtain long DNA information. Multiple genetic abnormalities such as gene variation, chromosome aneuploidy and chromosome structure rearrangement can be directly detected in embryos without pre-experiment of family members, so as to achieve universal normalization of the three PGT methods and solve the PGT detection needs of patients with multiple genetic diseases.

Enrollment

55 estimated patients

Sex

All

Ages

20 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients undergoing PGT cycle;
  2. Patients with balanced chromosomal structural rearrangement (reciprocal translocation, Robertsonian translocation, inversion, etc.) by conventional karyotype analysis;
  3. Clearly diagnosed monogenic genetic disease, and the related genes and their mutations are judged to be pathogenic or likely pathogenic;
  4. Chromosomal abnormalities in recurrent abortion tissues or in PGT-A embryos; The number of blastocysts was >= 1, and the morphological classification was more than 4BC/4CB.

Exclusion criteria

  1. Belonged to any contraindications of PGT;
  2. Failed to embryo biopsy;
  3. Failed to embryo WGA failure or abnormal quality control;
  4. Failed to embryo sequencing, and the result was unknown.

Trial contacts and locations

1

Loading...

Central trial contact

Liushan Ou; Ping Yuan, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems